(Q34394951)

1 August 2017

1 reference

title

The pathobiology of pulmonary hypertension. Endothelium (English)

1 reference

1 August 2017

0 references

Tuder RM

1

1 reference

1 August 2017

Cool CD

2

1 reference

1 August 2017

Yeager M

3

1 reference

1 August 2017

Taraseviciene-Stewart L

4

1 reference

1 August 2017

Bull TM

5

1 reference

1 August 2017

Voelkel NF

6

1 reference

1 August 2017

1 September 2001

1 reference

Clinics in Chest Medicine

1 August 2017

1 reference

1 August 2017

22

1 reference

1 August 2017

3

1 reference

1 August 2017

405-418

1 reference

Coagulation and fibrinolytic parameters in patients with pulmonary hypertension

1 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970280-X

7 January 2021

Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970280-X

7 January 2021

Isolation and characterization of neutralizing monoclonal antibodies to human vascular endothelial growth factor/vascular permeability factor121 (VEGF/VPF121)

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970280-X

7 January 2021

Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970280-X

7 January 2021

A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970280-X

7 January 2021

The histopathology of 36 cases of plexogenic pulmonary arteriopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970280-X

7 January 2021

An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970280-X

7 January 2021

Pathogenesis and evolution of plexiform lesions in pulmonary hypertension associated with scleroderma and human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970280-X

7 January 2021

Three-dimensional reconstruction of pulmonary arteries in plexiform pulmonary hypertension using cell-specific markers. Evidence for a dynamic and heterogeneous process of pulmonary endothelial cell growth

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970280-X

7 January 2021

Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970280-X

7 January 2021

Multiple mutation analyses in single tumor cells with improved whole genome amplification

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970280-X

7 January 2021

Nitric oxide-an endothelial cell survival factor.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970280-X

7 January 2021

Attenuated hypoxic pulmonary hypertension in mice lacking the 5-hydroxytryptamine transporter gene.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970280-X

7 January 2021

A role for the serotonin transporter in hypoxia-induced pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970280-X

7 January 2021

Prothrombotic mechanisms in primary pulmonary hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970280-X

7 January 2021

Pulmonary prostacyclin synthase overexpression in transgenic mice protects against development of hypoxic pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970280-X

7 January 2021

Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970280-X

7 January 2021

Expression of endothelin-1 in the lungs of patients with pulmonary hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970280-X

7 January 2021

Vascular endothelial growth factor signals endothelial cell production of nitric oxide and prostacyclin through flk-1/KDR activation of c-Src

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970280-X

7 January 2021

Prostacyclin receptor-dependent modulation of pulmonary vascular remodeling

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970280-X

7 January 2021

Transfection of inducible nitric oxide synthase gene causes apoptosis in vascular smooth muscle cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970280-X

7 January 2021

Biochemical reaction products of nitric oxide as quantitative markers of primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970280-X

7 January 2021

BMP2-induced apoptosis is mediated by activation of the TAK1-p38 kinase pathway that is negatively regulated by Smad6

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970280-X

7 January 2021

Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970280-X

7 January 2021

Genetic instability occurs in the majority of young patients with colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970280-X

7 January 2021

Endothelial dysfunction in pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970280-X

7 January 2021

High expression of endothelial nitric oxide synthase in plexiform lesions of pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970280-X

7 January 2021

Genomic instability in the type II TGF-beta1 receptor gene in atherosclerotic and restenotic vascular cells

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970280-X

7 January 2021

Pulmonary hypertension: newer concepts in diagnosis and management.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970280-X

7 January 2021

Mapping of familial primary pulmonary hypertension locus (PPH1) to chromosome 2q31-q32

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970280-X

7 January 2021

Localization of the gene for familial primary pulmonary hypertension to chromosome 2q31–32

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970280-X

7 January 2021

Discrimination between multicentric and multifocal carcinomas of the breast through clonal analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970280-X

7 January 2021

Primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970280-X

7 January 2021

Tissue factor expression by endothelial cells in sickle cell anemia

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970280-X

7 January 2021

Circulating activated endothelial cells in sickle cell anemia

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970280-X

7 January 2021

The role of vascular injury and hemodynamics in rat pulmonary artery remodeling

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970280-X

7 January 2021

Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970280-X

7 January 2021

Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970280-X

7 January 2021

Pulmonary hypertension and inflammation.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970280-X

7 January 2021

Expression of angiogenesis-related molecules in plexiform lesions in severe pulmonary hypertension: evidence for a process of disordered angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970280-X

7 January 2021

Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970280-X

7 January 2021

Monoclonal endothelial cells in appetite suppressant-associated pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970280-X

7 January 2021

Cellular and molecular mechanisms in the pathogenesis of severe pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970280-X

7 January 2021

Severe pulmonary hypertensive diseases: a perspective

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970280-X

7 January 2021

Hypoxia-induced pulmonary vascular remodeling: a model for what human disease?

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970280-X

7 January 2021

Hypoxia inhibits gene expression of voltage-gated K+ channel alpha subunits in pulmonary artery smooth muscle cells

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970280-X

7 January 2021

5-Lipoxygenase and 5-lipoxygenase activating protein (FLAP) immunoreactivity in lungs from patients with primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970280-X

7 January 2021

Impaired physiological responses to chronic hypoxia in mice partially deficient for hypoxia-inducible factor 1alpha

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970280-X

7 January 2021

cGMP-elevating agents suppress proliferation of vascular smooth muscle cells by inhibiting the activation of epidermal growth factor signaling pathway

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970280-X

7 January 2021

10.1016/S0272-5231(05)70280-X

Identifiers

DOI

1 reference

release_wkrofwrdxvczren6ubre44nnb4

1 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/wkrofwrdxvczren6ubre44nnb4

24 November 2022

mapped directly with Wikidata item

1 reference